Going universal
Celyad kicks antigen specificity out of the CAR
Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) is going allogeneic and ditching antigen specificity to broaden the reach of its chimeric antigen receptor (CAR)-expressing T cells. By suppressing endogenous T cell receptor (TCR) expression and using NK cell stress detectors instead of antigen receptors in its CARs, the company hopes to create individual products that can be used off-the-shelf to kill a wide range of solid and hematological cancers.
Formerly Cardio3 BioSciences S.A., Celyad began developing cancer immunotherapies after acquiring Celdara Medical LLC’s oncology division in 2015...
BCIQ Company Profiles